BioXcel Therapeutics, Inc. reported that on April 15, 2026, they granted warrants for 1,353,729 shares of common stock at $0.01 per share to lenders, following an amendment to their credit agreement dated March 27, 2026. This filing is significant as it indicates a financing move that could impact company resources.